產品詳情
查看大圖

  • 產品名稱：CRL-2505 22RV1 人前列腺癌細胞

  • 產品型號：CRL-2505
  • 產品廠商：其它品牌
  • 產品文檔：
你添加了1件商品 查看購物車
簡單介紹：
簡單介紹 CRL-2505 22RV1 人前列腺癌細胞、細胞係。細胞庫管理規範，提供的細胞株背景清楚，提供參考文獻和**培養條件!
詳情介紹：

CRL-2505 22RV1 人前列腺癌細胞 的詳細介紹
CRL-2505 22RV1 人前列腺癌細胞
ATCC® Number: CRL-2505™     Price:  
Designations: 22Rv1
Depositors:  JW Jacobberger
Biosafety Level: 2
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens (human)
Morphology: epithelial
Source: Organ: prostate 
Disease: carcinoma
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
 
Receptors: androgen receptor
Tumorigenic: Yes
Antigen Expression: prostate specific antigen (PSA)
DNA Profile (STR): Amelogenin: X,Y 
CSF1PO: 10,11 
D13S317: 9,12 
D16S539: 12 
D5S818: 11,12,13 
D7S820: 9,10,11 
THO1: 6,9.3 
TPOX: 8 
vWA: 15,21
Cytogenetic Analysis: 49,XY,del(1)(p10),+i(1)(q10),der(2)t(2;4)(p13;q31)del(2)(q13q33),der(4)t(2;4)(p13;q31),t(6;14)(q15;q32),+7,+12[5]/50,idem,+3[1]
Comments: 22Rv1 is a human prostate carcinoma epithelial cell line derived from a xenograft that was serially propagated in mice after castration-induced regression and relapse of the parental, androgen-dependent CWR22 xenograft. [46128] 
The cell line expresses prostate specific antigen (PSA). Growth is weakly stimulated by dihydroxytestosterone and lysates are immunoreactive with androgen receptor antibody by Western blot analysis. 
Growth is stimulated by epidermal growth factor (EGF) but is not inhibited by transforming growth factor beta-1 (TGF beta- 1). 
Recently , it has been shown that 22Rv1 prostate carcinoma cells produce high-titer of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus). [16173085]
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol:
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended 
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO 
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 40 hours
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
purified DNA:ATCC CRL-2505D
References: 46128: Sramkoski RM, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell. Dev. Biol. Anim. 35: 403-409, 1999. PubMed: 10462204
16173085: Knouf EC, et al. Multiple Integrated Copies and High-Level Production of the Human Retrovirus XMRV from 22Rv1 Prostate Carcinoma Cells. J. Virol. 83: 7353-7356, 2009. PubMed: 19403664

滬公網安備 31010902002433號